Peer-reviewed veterinary case report
Blood stem cell transplant treatment for dogs with B-cell lymphoma
By Willcox, J L et al.·Published in Journal of veterinary internal medicine·2012·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Autologous peripheral blood hematopoietic cell transplantation in dogs with B-cell lymphoma.
- Species:
- dog
Plain-English summary
A group of 24 dogs diagnosed with B-cell lymphoma underwent a special treatment called peripheral blood hematopoietic cell transplantation (PBHCT) after receiving high-dose chemotherapy. Most of the dogs (87.5%) successfully recovered and showed signs of improvement, with some remaining in remission for over a year. However, a few dogs faced complications, including two that sadly passed away during treatment. Overall, PBHCT appears to be a promising option for treating dogs with this type of cancer, helping many dogs live longer and healthier lives after their diagnosis.
People also search for: dog B-cell lymphoma treatment · PBHCT for dogs · dog cancer survival rates · canine lymphoma remission · dog chemotherapy side effects
Abstract
BACKGROUND: Peripheral blood CD34+ hematopoietic cell transplantation (PBHCT) is commonly used to treat human patients with relapsed non-Hodgkin diffuse, large B-cell lymphoma with cure rates approaching 50%. OBJECTIVE: To determine the safety and feasibility of performing PBHCT to treat canine B-cell lymphoma (LSA) patients in a clinical academic setting. ANIMALS: Twenty-four client-owned dogs diagnosed with B-cell LSA. METHODS: After high-dose cyclophosphamide and rhG-colony-stimulating factor treatment, peripheral blood mononuclear cells were collected using cell separator machines. The harvested cells then were infused after a 10 Gy dose of total body irradiation (TBI). Post-irradiation adverse effects were managed symptomatically and dogs were discharged upon evidence of engraftment. RESULTS: More than 2 × 10(6) CD34+ cells/kg were harvested in 23/24 dogs. Preapheresis peripheral blood monocyte count was correlated with the number of CD34+ cells/kg harvested. Twenty-one of 24 (87.5%) dogs engrafted appropriately, whereas 2 dogs (8.3%) died in the hospital. One (5%) dog exhibited delayed engraftment and died 45 days after PBHCT. One dog developed presumed TBI-induced pulmonary fibrosis approximately 8 months after PBHCT. The median disease-free interval and overall survival (OS) of all dogs from the time of PBHCT was 271 and 463 days, respectively. Five of 15 (33%) dogs transplanted before they relapsed remain in clinical remission for their disease at a median OS of 524 days (range, 361-665 days). CONCLUSIONS AND CLINICAL IMPORTANCE: In most cases, PBHCT led to complete hematologic reconstitution. Therefore, PBHCT may be considered as a treatment option for dogs with B-cell lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22882500/